Roche GLP-1 produces “robust” weight loss in late-stage obesity trial0 SHARESPosted: 29 January 2026 | Catherine Eckford (European Pharmaceutical Review) |The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients. Credit: Below the Sky / Shutterstock.comNew phase II findings uphold Roche’s once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist (GLP1-RA) as a promising obesity contender. The GLP-1 therapy provided a significant and clinically meaningful weight loss of 22.5 percent (efficacy estimand) in participants without reaching a weight loss plateau at 48 weeks. At Week 48, 95.7 percent achieved a weight loss of greater than or equal to five percent, with 87 percent achieving this level to 10, 47.8 percent 20 percent, and 26.1 percent 30 percent. CT-388 is also being investigated in an additional phase II study (CT388-104) to evaluate CT-388 in obesity or those with excess weight and have type 2 diabetes.